EMERYVILLE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. , (NTI(R)), a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates, today announced that Paul E. Freiman, President and Chief Executive Officer will make a company presentation at the Rodman & Renshaw 8th Annual Healthcare Conference in New York. The conference is being held November 6-8, 2006, at the New York Palace Hotel.
Mr. Freiman will present the NTI story on November 7, at 3:30 pm in the Villard Ballroom. The presentation will be web cast and available on the NTI website ( www.ntii.com ) at the following link:
http://www.shareholder.com/ntii/medialist.cfm
About Neurobiological Technologies, Inc.
NTI is a drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The Company’s strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized. NTI’s experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. We anticipate that we will continue to acquire and develop late-stage neurologic drug candidates and will develop the resources to market these drugs in selected world regions. Our goal is to develop and market drug candidates in the United States, Europe and Asia and we may seek partnerships with pharmaceutical and biotechnology companies to assist us.
Neurobiological Technologies, Inc.
CONTACT: Paul E. Freiman, President and CEO of NeurobiologicalTechnologies, Inc., +1-510-595-6000; or Marlon Nurse, VP, InvestorRelations, of Porter, LeVay & Rose, Inc., +1-212-564-4700, forNeurobiological Technologies, Inc.
Web site: http://www.ntii.com/
